In recent years, Novo Nordisk has been actively addressing the challenges arising from the launch of its highly popular obesity therapy, Wegovy. However, the pharmaceutical company is now venturing into a less common medical territory with its latest FDA approval. Novo has received FDA approval for Rivfloza, a treatment designed for the rare disease known as primary hyperoxaluria type 1 (PH1). This announcement comes as Novo Nordisk continues to make strides in the field of RNA interference (RNAi) drugs, with Rivfloza being a monthly subcutaneous treatment.
Following the FDA’s approval of Alnylam’s RNAi therapy Oxlumo in November 2020, this marks the second FDA-app...
